Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RM191A topical spray for neuropathic pain
ACTRN12617000206325Phase 2Recruiting
- Sponsor
- RR MedSciences
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RM191A in Neuralgia (2 arms), sponsored by RR MedSciences. Primary endpoint: Change in patient-reported neuropathic pain intensity. Started Sep 2017; status: recruiting.
02
Drugs
RM191A
03
Conditions
Neuralgia
Beyond the preview
Go deeper on ACTRN12617000206325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000206325.